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Effect of ambient particulate matter exposure
on hemostasis
EMILY COZZI, CHRISTOPHER J. WINGARD, WAYNE E. CASCIO, ROBERT B. DEVLIN,
JEREMY J. MILES, APRIL R. BOFFERDING, ROBERT M. LUST, MICHAEL R. VAN SCOTT, and
RUTH ANN HENRIKSEN
GREENVILLE AND RESEARCH TRIANGLE PARK, NC
Epidemiological studies have linked levels of particulate matter (PM) in ambient
air to cardiovascular mortality and hospitalizations for myocardial infarction (MI)
and stroke. Thrombus formation plays a primary role in potentiating acute car-
diovascular events, and this study was undertaken to determine whether pul-
monary exposure to PM alters hemostasis. PM was collected from the Chapel Hill,
NC airshed and was administered to mice by intratracheal instillation at a dose
previously shown to exacerbate myocardial ischemia-reperfusion injury. Twen-
ty-four hours after exposure, an increase occurred in the number of circulating
platelets and plasma concentrations of fibrinogen and soluble P-selectin. The
concentration of tissue factor pathway inhibitor (TFPI) in plasma was decreased,
whereas the plasma concentration of plasminogen activator inhibitor (PAI-1)
was increased. Consistent with these observations, bleeding time from a tail-tip
transection was shortened. These results provide evidence that PM exposure
alters hemostasis in otherwise healthy animals and may thereby promote clot
formation and impede clot resolution in susceptible individuals. The results also
establish definite hemostatic endpoints that can be used to further investigate
the effects of dose and particle characteristics on the toxicity of ambient parti-
cles. (Translational Research 2007;149:324–332)
Abbreviations: CBC  complete blood count; ELISA  enzyme-linked immunosorbent assay; ICR
 Institute for Cancer Research; MI  myocardial infarction; PAI-1  plasminogen activator
inhibitor; PBS  phosphate-buffered saline; PM  particulate matter; SE  standard error; sP-
selectin  soluble P-selectin; TAT  thrombin/antithrombin; TF  tissue factor; TFPI  tissue factor
pathway inhibitor; tPA tissue-type plasminogen activator; US-EPA United States Environmental
Protection Agency
G lobal epidemiological studies have linkedambient particulate matter (PM) exposure tocardiac arrhythmia, myocardial infarction
(MI), cardiac arrest, heart failure, and mortality because
of ischemic heart disease.1–3 Empirical evidence col-
lected over the past decade also indicates that airborne
PM can affect cardiovascular function and may thereby
contribute to the pathogenesis of cardiovascular dis-
ease.4–12
Ambient PM comprises a heterogeneous mixture of
substances, including carbon, metals, nitrates, sulfates,
organic compounds, and components of biogenic ori-
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gin.13,14 PM is derived from several different sources,
including combustion products from gasoline and die-
sel engines, coal- and oil-fired power plants, biomass
burning (eg, fireplaces and forest fires), and natural
sources such as wind-blown dust or crushing of crustal
materials.13,15–18 The US-EPA, currently regulates PM
levels on the basis of mass in 2 size ranges: “coarse”
PM (2.5–10 microns in diameter) and “fine” PM (0.1–
2.5 microns in diameter).13 However, increasing atten-
tion is being placed on smaller “ultrafine” particles,
with a diameter of less than 0.1 micron.13 Although
these particles contribute very little to PM mass, they
dominate particle number and surface area metrics.13,19
Furthermore, some have suggested that these smaller
particles can more readily exit the lung, where they
may directly affect cells and organs of the cardiovas-
cular system.20
Inhalation of PM has been shown to activate pulmo-
nary endothelium, macrophages, and neutrophils.21–23
Pulmonary inflammation acts as a catalyst for subse-
quent systemic inflammation.21,22,24 Studies in humans
and animals have demonstrated that PM increases the
release of neutrophils from bone marrow and the num-
ber of subsequently circulating neutrophils.19,25 Relo-
cation from an environment with high PM levels to one
with negligible PM reverses this effect.26 PM exposure
has also been shown to increase C-reactive protein
expression, plasma viscosity, and the progression of
atherosclerotic lesions.13,22,27–30 Furthermore, exposure
to concentrated ambient particles has been associated
with increased oxidative stress, altered vascular reac-
tivity, and alterations in hemostasis, which are strongly
associated with adverse cardiovascular effects.10,31–34
Recent studies indicate that exposure to PM also
promotes thrombus formation. Nemmar et al20 have
shown that PM from diesel exhaust activates platelets
and promotes femoral venous thrombosis in a dose-
dependent manner in hamsters. Likewise, Radomski
et al35 observed that exposure to carbon particles aug-
mented thrombosis in rats. Addition of these particles
directly to human platelets induced platelet aggregation
via adenosine 5=-diphosphate-, matrix metalloprotein-
ase-, or protein kinase C-dependent pathways.35 This
study was undertaken to elucidate effects of ambient
particulate matter on systemic factors involved in he-
mostasis and thereby to define discrete endpoints that
can be used to further investigate the toxicity of air-
borne particles.
MATERIALS AND METHODS
Animals. For this study, 6- to 10-week-old male Institute
for Cancer Research (ICR) mice were obtained from Harlan
(Indianapolis, Ind), housed in microisolation, and cared for by
the East Carolina University Comparative Medicine staff. All
protocols conformed to the standards in the National Insti-
tutes of Health’s “Guide for the Care and Use of Laboratory
Animals” and were approved by the East Carolina University
Institutional Committee on the Care and Use of Laboratory
Animals.
Particle collection and extraction. Particles were col-
lected as described by Cozzi et al.10 Briefly, particles were
collected over 7-day periods, during October 2002, in Chapel
Hill, NC with a ChemVol High Volume Cascade Impactor
(Rupprecht and Patashnick Co., Inc., East Greenbush, NY).
Particles (less than 0.15 m in diameter) were collected onto
G5300 filters (Monandock Non-Wovens LLC, Mt. Pocono,
Penn), dried under sterile conditions, and stored at 80°C
until extracted. Particles were extracted by prewetting the
filter with 70% ethanol, and endotoxin-free water was added
to yield a total volume of 40 mL. Extraction efficiency was
65–70%. The substrate–water solution was sonicated, and the
particle extract was concentrated by lyophilization and stored
at 80°C. Extracts were reconstituted to a concentration of 5
mg/mL in water and stored at 80°C. Four consecutive
weeks of extracts were pooled into monthly batches. These
particles exhibit a total carbon mass fraction of just over 22%;
high levels of arsenic, bromide, selenium, sulfur, and zinc;
and low levels of iron and titanium (unpublished data). Par-
ticle endotoxin levels were measured with a chromogenic
limulus amebocyte lysate endpoint assay (QCL-1000; Cam-
bex, Rockland, Me) according to kit instructions. No detect-
able levels of endotoxin were found on the particles.
Particulate exposure. Mice were exposed to PM as de-
scribed by Cozzi et al.10 Briefly, mice were anesthetized with
vapors from isoflurane/propanediol and a suspension of 100 g
of PM in 100 L of sterile phosphate-buffered saline (PBS)
(composition in mM: NaCl, 137; NaH2PO4, 10; KH2PO4, 1.47;
KCl, 2.7; pH adjusted to 7.4) was prepared and delivered by
intratracheal instillation. This dose of PM was previously shown
to elicit pulmonary and cardiovascular effects in ICR mice.10
Vehicle-exposed mice received 100 L of sterile PBS.
Complete blood count (CBC). Twenty-four hours after
exposure, a cardiac blood draw was performed in mice eu-
thanized by intraperitoneal injection of sodium pentobarbital
as adapted from Hoff et al.36 Blood was drawn to a total
volume of 1 mL using a 25-gauge needle attached to a 1-mL
syringe containing 100 L of 3.8% sodium citrate as an
anticoagulant. A CBC was determined on whole blood using
a Coulter Counter (Beckman Coulter, Fullerton, Calif). Cell
counts were corrected for anticoagulant dilution, averaged
between groups, and reported.
Platelet/monocyte interaction. Blood collected 24 h af-
ter exposure from a separate set of mice was placed in
PGE1-K2EGTA anticoagulant tubes and then divided for sub-
sequent analyses. For flow cytometry analysis of CD41, red
blood cells were lysed by adding Optilyse C (Beckman
Coulter) in a 1:1 ratio and 50 L of the blood/Optilyse C
solution was incubated with a fluorescent-conjugated anti-
body against CD41 (anti-mouse CD41-FITC; BD Bio-
sciences, San Jose, Calif) or a matched isotype control anti-
body (IgG1-FITC; BD Biosciences). The monocyte cell gate
was determined by forward- and side-scatter parameters. Flu-
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orescence within this gate was analyzed by flow cytometry
(FACScan; Becton Dickinson, San Jose, Calif), and mean
fluorescence intensity was calculated and reported.
Plasma fibrinogen levels. Whole blood remaining after
CBC analyses was centrifuged at 5000 g for 10 min, and
plasma was removed. Plasma fibrinogen levels in fresh
plasma were determined by a modified thrombin time as
described by Clauss et al.37 Briefly, 100 L of diluted plasma
was incubated at 37°C within the Coag-A-Mate XM coagu-
lation timer (Biomerieux, Durham, NC) before the addition of
100 L of Fibriquik thrombin reagent (Biomerieux) to induce
coagulation. Clotting times were converted to fibrinogen level
based on a human fibrinogen standard curve. Mean fibrinogen
levels for each mouse group were calculated and reported.
Plasma thrombin/antithrombin (TAT) levels. Twenty-four
hours after exposure, plasma TAT complex concentrations
were determined with a human TAT complex-specific sand-
wich enzyme-linked immunosorbent assay (ELISA) known to
cross-react with mouse TAT antigen according to kit instruc-
tions (Enzygnost kit; Dade Behring, Marburg, Germany).38,39
Briefly, 50 L of citrated plasma were incubated in 96 well
plates coated with human thrombin-specific antibody. After
addition of a peroxidase conjugated antibody to human anti-
thrombin and color development, the optical density of the
plate was read at 492 nm using a spectrophotometer (Smart-
Spec 3000; Bio-Rad, Hercules, Calif). A negative control
containing sample buffer was also used to establish a back-
ground spectrophotometer reading at 492 nm, which was
subtracted from sample readings, and TAT complex concen-
trations were determined based on a human TAT complex
standard curve (2–60 ng/mL) supplied with the kit. Mean
plasma TAT concentrations were calculated and reported.
ELISAs for plasma soluble P-selectin (sP-selectin),
plasma tissue factor pathway inhibitor (TFPI), plasma tis-
sue-type plasminogen activator (tPA), and plasminogen
activator inhibitor (PAI-1). Blood collected via cardiac punc-
ture was placed in collection tubes containing 7.5% ED-
TA(K3) anticoagulant (Kendall Monoject 10.25  50 mm;
Tyco Healthcare Group LP, Mansfield, Mass) and centrifuged
at 5000 g for 10 min to obtain plasma. Plasma sP-selectin,
tPA, and PAI-1 concentrations were determined by using
commercially available ELISA kits according to the manu-
facturers’ instructions (Quantikine kit; R&D systems, Minne-
apolis, Minn; Molecular Innovations, Southfield, Mich).
Plasma TFPI concentrations were determined by coating 96
well plates with 1:20 diluted plasma in 1% bovine serum
albumin in PBS. Rabbit anti-mouse TFPI IgG (1:500; Amer-
ican Diagnostica, Inc., Stamford, Conn), goat anti-rabbit IgG
peroxidase conjugate (1:12,000; Sigma-Aldrich, St. Louis,
Mo), and 3,3= 5,5= Tetramethylbenzidine substrate reagent
(BD Biosciences) were used for detection. Plate absorbance
was measured at 450 nm using a microplate reader (Bench-
mark Microplate Reader; Bio-Rad). Specificity of the anti-
TFPI antibody was confirmed by immunoprecipitation as
described by Michielsen et al.40
Bleeding time determination by tail-tip transaction. An-
alysis of bleeding from an induced injury was conducted as
described by Sato et al.41 Twenty four hours after exposure,
mice were anesthetized with sodium pentobarbital (50 mg/kg
initial dose, 30 mg/kg if supplemental doses were needed),
and tail-tips, 5 mm from their distal end, were surgically
transected using a scalpel blade. Tails were immediately
placed in a tube containing 10 mL of saline warmed to 37°C,
and a timer was started. The bleeding time was recorded as
the time required for initial stoppage of blood flow. Average
bleeding times were calculated and reported for each mouse
group. Overall, 20 min after tail transection, blood collected
in saline was hemolyzed and the absorbance at 546 nm was
used to determine blood volume loss.
Statistics. Values were reported as mean  standard error
(SE). Differences between groups were compared using the
Student t-test for unpaired observation or analysis of variance
with the Fisher exact test for least significant difference. In all
cases, a P value of less than 0.05 was used to indicate
statistical significance between groups.
RESULTS
Particulate matter effects on circulating blood cell
counts. Total leukocyte counts decreased 24 h after PM
exposure (vehicle, 5620  310 cells/mL whole blood;
PM, 4608  331 cells/mL whole blood; P  0.026).
These results were consistent with previous findings
and confirmed effective delivery of PM.10 It should be
noted that, in some animal studies, increases in circu-
lating polymorphonuclear cells with PM exposure have
been reported.22,42 For shorter time intervals after PM
exposure, it has been reported that circulating neutro-
phils enter the lungs, which could explain the reduction
in total leukocyte counts observed.43
In contrast, circulating platelet numbers in exposed
mice increased slightly compared with vehicle controls
(Fig 1, A). As PM exposure did not alter circulating RBC
number (vehicle, 818,400  168,465 cells/mL whole
blood; PM, 824,333  139,081 cells/mL whole blood;
P  0.43), hemoglobin (vehicle, 13.1  0.3 g/dL; PM,
13.1  0.2 g/dL; P  0.95), or hematocrit (vehicle,
41.4  1.0%; PM, 41.8  0.9%; P  0.39), the results
indicate specific effects on neutrophils and circulating
platelets.
Effect of particulate matter on platelet and endothelial
activation. sP-selectin may be released by both acti-
vated platelets and endothelial cells.44,45 PM exposure
significantly increased plasma sP-selectin levels 24 h
after exposure (Fig 1, B). Interaction of platelets and
monocytes was examined as a more specific indicator
of platelet activation.46 Platelets were labeled with a
fluorescent-conjugated antibody specific for mouse
platelet glycoprotein IIb (CD41), and association with
monocytes was then analyzed by flow cytometry. PM
exposure did not alter the number of CD41-positive
platelets within the monocyte gate (Fig 2), indicating
that PM exposure did not increase binding between
platelets and monocytes.
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Effect of particulate matter on circulating coagulation
proteins. Fibrinogen is the soluble precursor of fibrin,
which plays a central role in platelet aggregation and
clot formation.47 Plasma fibrinogen levels from blood
samples obtained via cardiac puncture 24 h after PM or
vehicle exposure were significantly increased com-
pared with the vehicle control group (Fig 3).
Thrombin is a serine protease that not only converts
soluble fibrinogen into insoluble fibrin, but also it pro-
motes platelet aggregation during clot formation.48
Thrombin activity is inhibited when antithrombin binds
irreversibly to thrombin forming a TAT complex.49 As
thrombin is the terminal protease in the coagulation
cascade, analysis of TAT complex concentrations
within the plasma serves as an indication of coagulation
pathway activation.50 Plasma TAT concentrations were
unchanged 24 h after PM exposure (Fig 4), indicating
the lack of ongoing thrombin generation.
TFPI, a glycoprotein released by endothelial cells,
Fig 2. Circulating platelet/monocyte interaction 24 h after PM or
vehicle exposure. Blood was drawn via cardiac puncture 24 h after
exposure. Platelets in each whole-blood sample were labeled with a
mouse-specific fluorescent-conjugated antibody against CD41. (A,
gate R1) Flow cytometry was performed, and the monocyte population
was gated based on forward and side scatter properties. (B) CD41
represents mean florescence intensity within the monocyte gate. Values
represent mean  SE, n  6 in each group, repeated in duplicate.
Fig 3. Plasma fibrinogen levels 24 h after PM or vehicle exposure.
Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. Plasma fibrinogen levels were determined by a
modified thrombin time. Values represent mean fibrinogen concen-
trations  SE, n  11 vehicle control and 9 PM exposed animals.
Fig 1. Total platelet number and plasma sP-selectin levels 24 h after
exposure. Mice were exposed to vehicle or 100 g of PM by
intratracheal instillation. (A) Blood was drawn via cardiac puncture
24 h after exposure, and a CBC was performed on each whole-blood
sample. Values represent mean platelet numbers  SE, n  11
vehicle control and n 9 PM exposed animals. (B) Blood was drawn
via cardiac puncture 24 h after exposure, and plasma was prepared
and assayed with a commercially available mouse specific sP-selectin
ELISA kit. Values represent mean  SE, n  6 in each group,
repeated in duplicate.
Translational Research
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inhibits TF-initiated clotting by binding factor Xa and
the TF/VIIa complex, thus inhibiting subsequent
thrombin production.51,52 Plasma TFPI levels were de-
creased significantly 24 h after PM exposure when
compared with vehicle control (Fig 5).
Effect of particulate matter on the fibrinolytic path-
way. Tissue-tPA converts plasminogen into the active
protease plasmin, which leads to degradation of fibrin
and subsequent vascular thrombus dissolution.53 PM
exposure did not change circulating tPA levels 24 h
after exposure (Fig 6, A). PAI-1 is a member of the
serine protease inhibitor family and is the primary
inhibitor of tPA.54 Thus, PAI-1 serves to inhibit fibri-
nolysis and clot dissolution. PM exposure significantly
increased circulating PAI-1 levels above vehicle 24 h
after exposure (Fig 6, B).
In vivo analysis of particulate matter exposure on he-
mostasis. In mice, the length of time that blood flows
from an induced vascular injury is indicative of the
levels of coagulation factors as well as of platelet and
endothelial activity.55 Bleeding time from a tail-tip
transection was therefore assessed as an in vivo indica-
tor of hemostasis. Mice were exposed to PM or vehicle,
and 24 h after exposure, tail-tips were transected and
bleeding times were measured. Bleeding times were
significantly shortened after PM exposure when com-
pared with vehicle controls (Fig 7), indicating that the
propensity for clot formation was enhanced. The total
blood loss 20 min after tail-tip transection was not
significantly different between PM exposed and control
groups (results not shown).
Fig 4. Plasma TAT concentrations 24 h after vehicle or PM expo-
sure. Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. TAT plasma concentrations were determined
with a commercially available ELISA kit. Values represent mean
TAT concentrations  SE, n  10 in each group.
Fig 5. Plasma TFPI absorbance 24 h after vehicle or PM exposure.
Blood was drawn via cardiac puncture 24 h after exposure, and
plasma was prepared. TFPI concentrations were determined by sand-
wich ELISA. Values represent mean TFPI concentration  SE, n 
7 vehicle control and 6 PM exposed animals, repeated in triplicate.
Fig 6. Plasma tPA absorbance and PAI-1 concentrations 24 h after
vehicle or PM exposure. Blood was drawn via cardiac puncture 24 h
after exposure, and plasma was prepared. Tissue plasminogen acti-
vator concentrations were determined with a commercially available
ELISA kit and mean sample absorbance  SE is shown, assays
repeated in duplicate, n  21, vehicle control and 17 PM exposed
animals (A). PAI-1 concentrations were determined with a commer-
cially available ELISA kit (B). Values represent mean PAI-1 con-
centrations  SE, n  13 vehicle control and 8 PM exposed animals,
repeated in duplicate.
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DISCUSSION
Studies have linked human exposure to air pollution
with increased cardiovascular mortality because of
ischemic heart disease, heart failure, arrhythmia, and
cardiac arrest.13 Increases in air pollution have also
been associated with an increased incidence of hospi-
talization for these same cardiovascular complications
24 h after peak ambient pollution levels.13 Population-
based studies by Liao et al56 have shown that short-
term exposure to coarse PM was positively associated
with plasma inflammatory and hemostatic risk factors
for cardiovascular disease. Although evidence suggest-
ing a link between pollution and hypercoagulability is
accumulating, there is still little evidence to suggest
that PM directly affects the clotting cascade in other-
wise healthy animals. The results of this study provide
evidence that pulmonary exposure to ambient PM in-
duces acute-phase inflammation and alters hemostatic
factors associated with blood clot formation and reso-
lution.
Multiple observations from this study support the
concept that exposure to PM induces a state of hyper-
coagulability conducive to thrombus formation in
healthy animals. The number of circulating platelets,
the concentration of sP-selectin, and fibrinogen in
plasma were increased by PM exposure (Figs 1 and 3).
The amount of TFPI in plasma, which should down-
regulate the activity of the tissue factor pathway, was
reduced by PM exposure (Fig 5). Plasma tPA level
was unchanged (Fig 6, A), but plasma PAI-1 level was
increased (Fig 6, B), which is expected to decrease the
activity of available tPA. The time for coagulation to
occur was decreased after PM exposure, as indicated by
shorter bleeding times after tail-tip transection (Fig 7).
Thus, PM exposure induced multiple procoagulant
changes predicted to contribute to an environment con-
ducive to thrombus formation.
Alterations in platelet number and function play a
pivotal role in the pathogenesis of acute coronary syn-
dromes.57,58 Increases in platelet number, size, and
activity are considered risk factors for MI.59–61 Reed
et al15 has shown that total platelet numbers were
increased in rodents exposed to hardwood smoke by
whole-body inhalation. The increase in platelet number
observed in response to PM exposure was consistent
with these earlier studies, but the increase was small
and unlikely to be clinically relevant by itself. Platelet
activation has also been shown to be altered with PM
exposure. Nemmar et al20 have demonstrated that cir-
culating platelets were directly activated by interacting
with diesel exhaust particles. It should be noted that
some studies have not demonstrated an increase in
circulating platelet number or activity with PM expo-
sure.20,62 This discrepancy could be a result of differ-
ences in exposure methods, duration of administration,
dose administered, time of measurement, or innate
characteristics of PM used in those studies. sP-selectin
can facilitate procoagulant activity,44,45,63 and in-
creased sP-selectin levels have been linked to acute
myocardial infarction, peripheral arterial occlusive dis-
ease, plaque destabilization, and atrial fibrillation.64–68
sP-selectin is typically thought to be an indicator of
platelet activation state. However, Burger et al45 have
demonstrated that the primary source of circulating
P-selectin may be activated endothelial cells. In either
case, sP-selectin levels serve as a marker of an acti-
vated vasculature/blood interface that would promote
thrombus formation.
In contrast to the results in this study, Khandoga
et al69 demonstrated that PM administered intrave-
nously did not increase endothelial expression of P-
selectin in mice, although sP-selectin was not mea-
sured. Their findings may be related to the time of
assessment or the route of administration, resulting in a
lack of appreciable pulmonary inflammation in their
model.13 A link between sP-selectin levels and the
degree of pulmonary inflammation in response to PM
exposure is an interesting concept because it suggests
that the capacity of PM to alter thrombogenic potential
may be linked to a generalized inflammatory condition
as opposed to a specific effect of the particles. More
studies must be conducted to test this hypothesis.
Increased fibrinogen levels have been associated with
the progression of atherosclerotic lesions and are con-
sidered a risk factor for future cardiovascular events.47
The results of this study (Fig 3) are consistent with
human ambient particle exposure studies by Ghio
et al,34 in which plasma fibrinogen levels were in-
creased 24 h after particle inhalation. Thus, adminis-
Fig 7. Bleeding times 24 h after vehicle or PM exposure. Tail-tips
were surgically transected 24 h after exposure and bleeding time was
measured. Values for bleeding time represent mean bleeding time 
SE, n  12 in each group.
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tration of PM by either inhalation or instillation resulted
in increased fibrinogen levels.
Increased TAT complex concentrations within the
plasma are indicative of activation of the coagulation
pathway.50 In human studies, increased TAT levels
have been linked to MI, unstable angina, and atrial
fibrillation.70 TAT concentrations measured 24 h after
PM exposure were not altered compared with control
values (Fig 4), indicating that at the time point inves-
tigated evidence for activation of the coagulation path-
way was not detected. These results are in agreement
with those of Nadziejko et al,71 who demonstrated that
inhaled fine PM did not affect plasma TAT levels in
rats at 12 and 24 h post-exposure.
TFPI is a glycoprotein that is released primarily by
activated endothelial cells and acts as a primary inhib-
itor of clot formation by inhibiting thrombin produc-
tion.51,52 In this study, plasma TFPI was significantly
decreased after PM exposure (Fig 5). This report is the
first to address the ability of PM to alter TFPI protein
expression. Decreased TFPI levels have recently been
linked to an increased risk of deep vein thrombosis in
humans.72
Occlusion of microvessels in vivo is affected by both
thrombus formation and resolution. Observations indi-
cate that PM exposure may also affect the resolution of
clots through alteration of the fibrinolytic pathway. tPA
converts plasminogen to plasmin, which promotes clot
lysis.73 PAI-1 is the major inhibitor of tPA and thereby
promotes clot retention.54 Although plasma tPA levels
were unaltered, plasma PAI-1 levels were increased
significantly, which would be expected to impair fibri-
nolysis (Fig 6). Increased PAI-1 levels and subse-
quently impaired fibrinolysis are associated with car-
diovascular disease, insulin resistance, and abdominal
obesity.54,73,74 This study is the first demonstration that
PM exposure can alter the expression of inhibitors of
both clot formation and resolution in a procoagulant
manner.
Hemostasis is a balance between coagulation and
fibrinolytic processes.75 Therefore, a tail-tip transection
was performed as an overall indication of the effect of
PM exposure on hemostasis in vivo. In this study, it was
demonstrated that bleeding time was significantly re-
duced 24 h after PM exposure (Fig 7). Bleeding time is
a function of vascular reactivity, coagulation status, and
platelet function.76 The lack of significant difference in
total blood loss between the experimental and control
groups is consistent with the presence of only a mild
thrombotic tendency in the PM-exposed animals. In
this study, evidence of altered endothelial function in-
cludes reduced plasma TFPI, increased sP-selectin, and
increased PAI-1 expression. In addition, it was previ-
ously demonstrated that aortic relaxation to acetylcho-
line is impaired 24 h after PM exposure.10 Platelet
number in this model was increased; however, platelet
activation was not detected as evidenced by the absence
of an increase in platelet/monocyte adhesion deter-
mined by flow cytometry. Thus, the reduction in bleed-
ing time observed in this model may be due primarily
to endothelial activation and subsequent prothrombotic
alterations in coagulation factors responsible for clot
formation and resolution. It is important to note that
bleeding times have been used extensively to study
pharmacologic, pathophysiologic, and genetic alter-
ations in hemostasis in humans and animals.76 These
results are consistent with studies that have looked
directly at clot formation in vivo. Nemmar et al20 dem-
onstrated that intratracheal diesel exhaust particle
exposure enhanced arterial and venous thrombus for-
mation in an in vivo endothelial injury model. Likewise,
Radomski et al35 showed that exposure to nanoparticles
resulted in increased thrombosis induced by ferric chlo-
ride endothelial injury in rat carotid arteries.
Speculations. Taken together, the results of this study
provide evidence that pulmonary exposure to PM alters
thrombogenic potential through effects on clot forma-
tion and resolution, which may be particularly relevant
in a setting of preexisting atherosclerotic disease in
which individuals are susceptible to thrombus forma-
tion and vessel occlusion. Furthermore, the results de-
fine a set of easily measured hemostatic parameters by
which particle exposure time courses and particle tox-
icity may be further investigated.
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